Table 5. Effect of cirrhosis on the likelihood of a sustained virological responsea to generic direct-acting agents in patients with hepatitis C, meta-analysis, 2019.
| Studyb | No. of patients with a response/no. treated |
RR (95% CI) | Study weighting (%) | |
|---|---|---|---|---|
| Without cirrhosis | With cirrhosis | |||
| Yakoot et al., 201639 | 37/37 | 9/11 | 1.19 (0.90–1.58) | 1.87 |
| Nagral et al., 201734 | 22/22 | 3/4 | 1.20 (0.77–1.87) | 0.88 |
| Zeng et al., 201741 | 125/129 | 61/63 | 1.00 (0.95–1.06) | 11.00 |
| Abozeid et al., 201823 | 245/247 | 143/148 | 1.03 (0.99–1.06) | 24.00 |
| Gupta et al., 201826 | 248/259 | 128/134 | 1.00 (0.96–1.05) | 22.64 |
| Liu et al., 201831 | 173/175 | 49/52 | 1.05 (0.98–1.12) | 10.14 |
| Liu et al., 2018)30 | 330/321 | 172/187 | 1.06 (1.01–1.11) | 29.47 |
| Pooled datac | 1180/1190 | 565/599 | 1.03 (1.01–1.06) | 100.00 |
CI: confidence interval; RR: relative risk.
a A response was defined as a sustained virological response 12 weeks after the end of treatment.
b The Merat et al.33 study was not included in this subanalysis because it involved only patients with cirrhosis.
c The I2 value for between-study heterogeneity was 0.0% (P = 0.435).